ArticleCancer medicine2026
A U-Shaped Association: The First-Year eGFR Slope and Mortality Risk in Multiple Myeloma.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundRenal impairment (RI) increases mortality risk in multiple myeloma (MM), yet RI represents a relatively late stage of kidney dysfunction. Whether early indicators of renal dysfunction, such as the estimated glomerular filtration rate (eGFR slope), predict mortality risk in MM remains unknown.
methodsThis single center, retrospective study included 974 newly diagnosed MM (NDMM) patients (2008-2022), with prospectively monitored creatinine levels and survival status over a median follow-up period of 40 months. The first-year eGFR slope, representing the average annual rate of eGFR change, was calculated by least-squares regression using all monitored eGFR values during the first year. Cox proportional-hazards regression and restricted cubic splines (RCS) analyses were used to explore the association of first-year eGFR slope with all-cause mortality. Subgroup analyses were stratified by first-year treatment response (partial response (PR) or better response group and less than PR group), and baseline eGFR strata (< 40, 40-90, and ≥ 90 mL/min/1.73 m
resultsIn the overall population, the first-year eGFR slope-mortality association exhibited a U-shaped pattern (p for nonlinearity 0.0145), indicating that excessive declines and increases in eGFR were linked to elevated mortality. This pattern was consistent across baseline renal function strata. Notably, the association varied substantially by treatment response: in the PR or better group, a rise in eGFR slope conferred a higher mortality risk (HR > 1 when annual increment exceeded 4.3 mL/min/1.73 m
conclusionsOverall, first-year eGFR slope demonstrates a U-shaped association with mortality in NDMM. Importantly, excessive eGFR elevation, particularly in patients achieving PR or better, is paradoxically associated with increased death risk, highlighting the need for response-stratified interpretation of renal dynamics to guide early clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.